Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Determination of tamoxifen and biologically active metabolites in human breast tumours and plasma.

× No keyword cloud information.

20 in total

Review 1. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors: P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal: Clin Pharmacokinet Date: 1992-05 Impact factor: 6.447

2. Electrospray ionization mass spectrometry for analysis of low-molecular-weight anticancer drugs and their analogues.

Authors: G K Poon; G M Bisset; P Mistry
Journal: J Am Soc Mass Spectrom Date: 1993-07 Impact factor: 3.109

3. Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy.

Authors: V Craig Jordan
Journal: J Natl Cancer Inst Date: 2014-09-30 Impact factor: 13.506

4. Effects of myricetin, an anticancer compound, on the bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats.

Authors: Cheng Li; Sung-Cil Lim; Jin Kim; Jun-Shik Choi
Journal: Eur J Drug Metab Pharmacokinet Date: 2011-03-27 Impact factor: 2.441

Review 5. Interactions between antiretrovirals and antineoplastic drug therapy.

Authors: Tony Antoniou; Alice L Tseng
Journal: Clin Pharmacokinet Date: 2005 Impact factor: 6.447

6. Expression of sulfotransferase isoform 1A1 (SULT1A1) in breast cancer cells significantly increases 4-hydroxytamoxifen-induced apoptosis.

Authors: Kelly E Mercer; Eugene O Apostolov; Goncalo Gamboa da Costa; Xinfeng Yu; Patrick Lang; Dean W Roberts; Warren Davis; Alexei G Basnakian; Fred F Kadlubar; Susan A Kadlubar
Journal: Int J Mol Epidemiol Genet Date: 2010-01-30

Review 7. Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications.

Authors: V C Jordan
Journal: Breast Cancer Res Treat Date: 1983 Impact factor: 4.872

Review 8. Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors: M M Buckley; K L Goa
Journal: Drugs Date: 1989-04 Impact factor: 9.546

9. Effect of continuous vs intermittent application of 3-OH-tamoxifen or tamoxifen on the proliferation of the human breast cancer cell line MCF-7 M1.

Authors: M Dietel; R Löser; P Röhlke; W Jonat; A Niendorf; D Gerding; A Kohr; F Hölzel; H Arps
Journal: J Cancer Res Clin Oncol Date: 1989 Impact factor: 4.553

10. Medroxyprogesterone acetate (MAP) and tamoxifen (TMX) plasma levels after simultaneous treatment with 'low' TMX and 'high' MAP doses.

Authors: C M Camaggi; E Strocchi; N Canova; B Costanti; F Pannuti
Journal: Cancer Chemother Pharmacol Date: 1985 Impact factor: 3.333